Pfizer [PFE] vs Gilead Sciences [GILD] Detailed Stock Comparison
Pfizer
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Pfizer wins in 10 metrics, Gilead Sciences wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Pfizer | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 17.05 | 24.06 | Pfizer |
| Price-to-Book Ratio | 1.48 | 7.44 | Pfizer |
| Debt-to-Equity Ratio | 68.84 | 130.79 | Pfizer |
| PEG Ratio | 8.03 | 15.41 | Pfizer |
| EV/EBITDA | 7.68 | 11.56 | Pfizer |
| Profit Margin (TTM) | 12.62% | 20.76% | Gilead Sciences |
| Operating Margin (TTM) | 35.17% | 38.49% | Gilead Sciences |
| EBITDA Margin (TTM) | 35.17% | 38.49% | Gilead Sciences |
| Return on Equity | 8.62% | 32.65% | Gilead Sciences |
| Return on Assets (TTM) | 4.79% | 12.14% | Gilead Sciences |
| Free Cash Flow (TTM) | $9.84B | $10.31B | Gilead Sciences |
| Dividend Yield | 5.32% | 2.84% | Pfizer |
| 1-Year Return | -16.18% | 49.71% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 2.14 | 4.96 | Pfizer |
| Enterprise Value | $179.15B | $158.60B | Pfizer |
| EV/Revenue Ratio | 2.87 | 5.52 | Pfizer |
| Gross Profit Margin (TTM) | 79.26% | 76.90% | Pfizer |
| Revenue per Share (TTM) | $11 | $23 | Gilead Sciences |
| Earnings per Share (Diluted) | $1.38 | $4.76 | Gilead Sciences |
| Beta (Stock Volatility) | 0.44 | 0.35 | Gilead Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Pfizer vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pfizer | 1.44% | 4.04% | -4.00% | 6.32% | -5.87% | -8.94% |
| Gilead Sciences | 8.27% | -1.79% | -1.34% | 11.51% | 14.83% | 20.03% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pfizer | -16.18% | -52.25% | -33.73% | -28.59% | 56.82% | -3.59% |
| Gilead Sciences | 49.71% | 75.16% | 60.99% | -4.60% | 542.66% | 940.38% |
Performance & Financial Health Analysis: Pfizer vs Gilead Sciences
| Metric | PFE | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $133.78B | $142.44B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 42,776,620 | 5,751,080 |
| 90 Day Avg. Volume | 39,994,427 | 6,288,790 |
| Last Close | $24.58 | $119.40 |
| 52 Week Range | $20.92 - $30.43 | $72.43 - $121.38 |
| % from 52W High | -19.22% | -1.63% |
| All-Time High | $61.71 (Dec 20, 2021) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -60.17% | -3.22% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.08% | 0.00% |
| Quarterly Earnings Growth | -0.05% | 0.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.21% |
| Operating Margin (TTM) | 0.35% | 0.38% |
| Return on Equity (TTM) | 0.09% | 0.33% |
| Debt to Equity (MRQ) | 68.84 | 130.79 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.89 | $15.39 |
| Cash per Share (MRQ) | $3.05 | $7.00 |
| Operating Cash Flow (TTM) | $13.99B | $10.37B |
| Levered Free Cash Flow (TTM) | $15.05B | $9.99B |
| Dividends | ||
| Last 12-Month Dividend Yield | 5.32% | 2.84% |
| Last 12-Month Dividend | $1.27 | $3.12 |
Valuation & Enterprise Metrics Analysis: Pfizer vs Gilead Sciences
| Metric | PFE | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 17.05 | 24.06 |
| Forward P/E | 8.03 | 15.41 |
| PEG Ratio | 8.03 | 15.41 |
| Price to Sales (TTM) | 2.14 | 4.96 |
| Price to Book (MRQ) | 1.48 | 7.44 |
| Market Capitalization | ||
| Market Capitalization | $133.78B | $142.44B |
| Enterprise Value | $179.15B | $158.60B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.87 | 5.52 |
| Enterprise to EBITDA | 7.68 | 11.56 |
| Risk & Other Metrics | ||
| Beta | 0.44 | 0.35 |
| Book Value per Share (MRQ) | $15.89 | $15.39 |
Financial Statements Comparison: Pfizer vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PFE | GILD |
|---|---|---|
| Revenue/Sales | $13.72B | $6.67B |
| Cost of Goods Sold | $2.85B | $1.54B |
| Gross Profit | $10.87B | $5.13B |
| Research & Development | $2.20B | $1.38B |
| Operating Income (EBIT) | $4.43B | $2.49B |
| EBITDA | $6.48B | $3.28B |
| Pre-Tax Income | $2.79B | $1.65B |
| Income Tax | $-189.00M | $334.00M |
| Net Income (Profit) | $2.97B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PFE | GILD |
|---|---|---|
| Cash & Equivalents | $1.43B | $7.93B |
| Total Current Assets | $45.86B | $16.90B |
| Total Current Liabilities | $36.45B | $12.34B |
| Long-Term Debt | $56.82B | $22.15B |
| Total Shareholders Equity | $90.64B | $19.08B |
| Retained Earnings | $119.59B | $10.93B |
| Property, Plant & Equipment | N/A | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PFE | GILD |
|---|---|---|
| Operating Cash Flow | $3.91B | $1.56B |
| Capital Expenditures | $-564.00M | $-104.00M |
| Free Cash Flow | $1.77B | $1.65B |
| Debt Repayment | $-2.43B | $-1.76B |
| Common Stock Repurchase | N/A | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | PFE | GILD |
|---|---|---|
| Shares Short | 99.27M | 22.54M |
| Short Ratio | 2.53 | 2.80 |
| Short % of Float | 0.02% | 0.02% |
| Average Daily Volume (10 Day) | 42,776,620 | 5,751,080 |
| Average Daily Volume (90 Day) | 39,994,427 | 6,288,790 |
| Shares Outstanding | 5.67B | 1.25B |
| Float Shares | 5.68B | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.68% | 0.90% |
Dividend Analysis & Yield Comparison: Pfizer vs Gilead Sciences
| Metric | PFE | GILD |
|---|---|---|
| Last 12-Month Dividend | $1.27 | $3.12 |
| Last 12-Month Dividend Yield | 5.32% | 2.84% |
| 3-Year Avg Annual Dividend | $1.52 | $3.04 |
| 3-Year Avg Dividend Yield | 1.27% | 0.93% |
| 3-Year Total Dividends | $4.55 | $9.12 |
| Ex-Dividend Date | Jan 24, 2025 | Jun 13, 2025 |